10.30 USD
▲+0.27+3.41%
盘后 9.96 0.00%
2026-08-03
市值
$635.54M
市盈率
—
EPS
-5.60
股息率
—
52 周区间
5.46 – 16.19
成交量
968.72K
Beta
0.94
目标价
24.27
52W 低 5.4652W 高 16.19
价格走势
公司简介
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12...